TRAIL and its receptors as targets for cancer therapy
Open Access
- 1 October 2004
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 95 (10) , 777-783
- https://doi.org/10.1111/j.1349-7006.2004.tb02181.x
Abstract
Tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptotic cell death in a variety of tumor cells by engaging the death receptors DR4 and DR5, while sparing most normal cells. Preclinical studies in mice and non‐human primates have shown the potential utility of recombinant soluble TRAIL and agonistic anti‐DR5 or DR4 antibodies for cancer therapy. Moreover, we have recently revealed a vital role for endogenously expressed TRAIL in immunosurveillance of developing and meta‐static tumors. In this review, we summarize recent knowledge about TRAIL and its receptors as promising targets for cancer therapy.This publication has 61 references indexed in Scilit:
- Oncogenic Ras Sensitizes Normal Human Cells to Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand-Induced ApoptosisCancer Research, 2004
- Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cellsOncogene, 2003
- Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2Cell Death & Differentiation, 2003
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase MaturationMolecular and Cellular Biology, 2003
- Identification of a New Murine Tumor Necrosis Factor Receptor Locus That Contains Two Novel Murine Receptors for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)Journal of Biological Chemistry, 2003
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996